About Us   |   Contact Us   |  
Submission  

Clinical and Biological Lupus Induced by Infliximab in Crohn's Disease

DOI : https://doi.org/10.36349/easjms.2024.v06i04.005
PDF
HTML
XML

The use of anti-TNFs in Crohn's disease (CD) is often associated with the appearance of antinuclear antibodies, and more rarely with anti-native DNA antibodies. Anti-TNF-induced lupus remains exceptional. We report the case of a 52-year-old woman, followed for colonic Crohn's disease, treated with Infliximab. After 12 months of treatment with anti-TNF alpha (Infliximab), the patient developed clinical and biological lupus with positive antinuclear antibodies (ANA) and anti-native DNA antibodies (IgG). Infliximab treatment was discontinued. Six months after stopping the treatment, the patient had no recurrence of clinical signs, and immunological examinations showed a marked decrease in total ANA and anti-native DNA antibodies (IgG).

TOP EDITORS

OPEN ACCESS JOURNALS

Dr. Afroza Begum

Lecturer, Dept. of Pharmacology and Therapeutics, Shaheed Monsur Ali Medical College & Hospital, Uttara, Dhaka-1230, Bangladesh

BEST AUTHOR

Of The Month

TRACK YOUR ARTICLE

Enter the Manuscript Reference Number (MRN)
Get Details

Contact us


EAS Publisher (East African Scholars Publisher)
Nairobi, Kenya


Phone : +91-9365665504
Whatsapp : +91-8724002629
Email : easpublisher@gmail.com

About Us


EAS Publisher (East African Scholars Publisher) is an international scholar’s publisher for open access scientific journals in both print and online publishing from Kenya. Its aim is to provide scholars ... Read More Here

*This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2020, All Rights Reserved | SASPR Edu International Pvt. Ltd.

Developed by JM